![Piotr Wysocki: [89Zr]Zr-girentuximab is highly sensitive and specific for clear-cell RCC imaging](https://oncodaily.com/pub/uploads/2024/09/Screenshot-2024-09-14-174634.png)
Piotr Wysocki: [89Zr]Zr-girentuximab is highly sensitive and specific for clear-cell RCC imaging
Piotr Wysocki recently shared a post on LinkedIn:
“A phase 3 trial, ZIRCON, evaluated the use of the monoclonal antibody [89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma (ccRCC). The [89Zr]Zr-girentuximab binds specifically to carbonic anhydrase 9 (CA9), a tumor antigen highly expressed in ccRCC.
The multinational ZIRCON trial was in nine countries and involved 332 enrolled patients. Participants had indeterminate renal masses measuring 7 cm or smaller and were scheduled for nephrectomy. Each patient received a single intravenous dose of [89Zr]Zr-girentuximab, followed by PET-CT imaging within five days. Histopathological diagnosis from surgery served as the reference standard for evaluating the sensitivity and specificity of the PET-CT results.
Key Findings
- Sensitivity and Specificity: The imaging technique showed a mean sensitivity of 85.5% and a mean specificity of 87.0% in detecting ccRCC. This indicates that [89Zr]Zr-girentuximab PET-CT was highly accurate in differentiating ccRCC from other renal masses.
- Safety Profile: The treatment was well tolerated, with no significant safety signals linked to [89Zr]Zr-girentuximab. Most adverse events occurred during or after surgery and were not related to the imaging agent.
- Adverse Events: The most common serious adverse events reported included post-procedural hemorrhage, urinary retention, and hypertension. Importantly, no treatment-related deaths were observed.
[89Zr]Zr-girentuximab PET-CT may significantly impact clinical decisions in ccRCC patients, maybe to a similar extent as 68Ga-PSMA-11 did in prostate cancer patients.”
Authors: Brian Shuch, Allan J Pantuck, Jean-Christophe Bernhard, Michael A Morris, Viraj Master, Andrew M Scott, Charles van Praet, Clement Bailly, Bülent Önal, Tamer Aksoy, Robin Merkx, David M Schuster, Sze Ting Lee, Neeta Pandit-Taskar, Alice C Fan, Phillip Allman, Karl Schmidt, Libuse Tauchmanova, Michael Wheatcroft, Christian Behrenbruch, Colin R W Hayward and Peter Mulders.
![Piotr Wysocki: [89Zr]Zr-girentuximab is highly sensitive and specific for clear-cell RCC imaging](https://oncodaily.com/pub/uploads/2024/09/Screenshot-2024-09-14-175341-800x581.png "Piotr Wysocki: [89Zr]Zr-girentuximab is highly sensitive and specific for clear-cell RCC imaging 1")
Source: Piotr Wysocki/LinkedIn
About Piotr Wysocki
Piotr Wysocki leads the Clinical Oncology Department at University Hospital and the Faculty of Oncology at Jagiellonian University-Medical College in Krakow, Poland. As an advisor to the Polish Ministry of Health, he shapes the national cancer strategy.
His clinical expertise spans the systemic treatment of breast, gynecologic, and genitourinary cancers, with a focus on developing innovative metronomic chemotherapy-based therapies for advanced cancer patients who have undergone prior treatment.
Read other posts by Piotr Wysocki published on OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023